// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

CORRELATION BETWEEN CD3+ T-CELLS IN CSF SAMPLES OF BLINATUMOMAB TREATED B ACUTE LYMPHOBLASTIC LEUKEMIA PEDIATRIC PATIENTS AND NEUROLOGICAL TOXICITY

Valentina Bertaina - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

CAPTURE-BASED NGS PANEL FOR DETECTION OF IMMUNOGLOBULIN AND T-CELL RECEPTOR GENE REARRANGEMENTS IN DNA SAMPLES FROM PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Hana Jelnkov - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

PHARMACOGENETIC STUDY OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

Judit C. Sagi - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

DEFINITION AND PROGNOSTIC IMPACT OF PH-LIKE AND IKZF1-PLUS FEATURES IN CHILDREN WITH DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKEMIA

Chiara Palmi - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

N/A

MINIMAL RESIDUAL DISEASE, CLINICAL OUTCOME, AND THE EFFECT OF IKZF1 DELETIONS IN PEDIATRIC DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKEMIA: AN INTERNATIONAL MATCHED PONTE DI LEGNO CASE-CONTROL STUDY

Naomi Michels - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute lymphoblastic leukemia

N/A

INOTUZUMAB OZOGAMYCIN IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS IN 56 PATIENTS TREATED IN GRAALL CENTERS

Sylvain Chantepie - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

SEQUENCING OF NOVEL AGENTS IN B-CELL ACUTE LYMPHOCYTIC LEUKEMIA (ALL): BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN HAVE COMPARABLE EFFICACY AS FIRST OR SECOND NOVEL AGENT THERAPY IN ALL

Talha Badar - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

SPECTRUM AND CLINICAL CHARACTERISTICS RELEVANCE OF GENE MUTATIONS IN CHINESE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

Diying Shen - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Methadone hydrochloride

LONG TERM FOLLOW-UP OF A COHORT OF PATIENTS WITH THERAPY RELATED ACUTE LYMPHOBLASTIC LEUKEMIA: CLINICAL CHARACTERISTICS AND SURVIVAL.

Brayan Merchan - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

INOTUZUMAB OZOGAMICIN WITH BOSUTINIB IN RELAPSED OR REFRACTORY PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE (CML-LBP)

Nitin Jain - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

CLONAL HETEROGENEITY AND RELATED CLINICAL STUDY IN ACUTE LYMPHOBLASTIC LEUKEMIA

Xiaodong Lyu - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

AN OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BLINATUMOMAB IN CHINESE ADULTS WITH RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Hongsheng Zhou - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

A HIGHER DOSE OF DASATINIB MAY INCREASE THE POSSIBILITY OF CROSSING THE BLOOD-BRAIN BARRIER IN THE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Xiaoyuan Gong - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

dasatinib

BLINATUMOMAB USE DURING CONSOLIDATION IN ADULT PATIENTS WITH HIGH-RISK, PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF THE BLIN01 TRIAL.

Josep Maria Ribera - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

LIVER SURVEILLANCE IN PATIENTS WHO RECEIVED INOTUZUMAB OZOGAMICIN (IO) FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Giovanni Marconi - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

FINAL ANALYSIS OF THE GMALL-PH-01 TRIAL: PHASE II STUDY OF STANDARD CHEMOTHERAPY IN COMBINATION WITH DASATINIB IN FIRST LINE TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Fabian Lang - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

LONGITUDINAL THERAPEUTIC DRUG MONITORING TO OPTIMIZE PEGASPARGASE DOSING IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Maria Moreno - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Pegaspargase

THE DEVELOPMENT OF GLOBAL PEDIATRIC ONCOLOGY GUIDELINES: A FOCUS ON THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN®) PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA GUIDELINES

Hiroto Inaba - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

OUTCOMES OF ADOLESCENT AND YOUNG ADULTS(AYA) WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ON A MODIFIED BFM-90 PROTOCOL- A SINGLE CENTRE EXPERIENCE

Akhil Rajendra - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Methotrexate

TAS2R30 AND DAAM2 GENE DELETERIOUS MUTATION MAY CAUSE ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN

Jieming Yu - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Copyright © 2026. QuantiNova All rights reserved